AstraZeneca plc vs Peloton Interactive Inc — how do they compare? AstraZeneca plc trades at $158.27 (market cap $248.14B), while Peloton Interactive Inc trades at $5.52 (market cap $2.46B). The key difference: AstraZeneca plc is far larger — about 100.9× Peloton Interactive Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Peloton Interactive Inc pays none. Which is the better fit depends on your goals.
| AZN | PTON | |
|---|---|---|
Market Cap | $248.14B | $2.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $9.00 |
52-Week Low | $147.06 | $3.71 |
Enterprise Value | $275.41B | $2.96B |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Peloton Interactive (PTON) trades at $5.51, down 2.99% on the day, reflecting ongoing investor caution despite achieving its first annual net profit in fiscal 2026. The stock shows a bearish technical trend with key support at $5, while fundamentals reveal a mixed picture: revenue declined to $2.49B in 2025 but net losses narrowed significantly, with a positive net income margin of 2.58% projected for 2026. Recent news highlights profitability milestones but also subscriber declines and a conservative 2027 outlook.
The outlook remains cautious; profitability improvements and cost control are positive, but persistent revenue erosion and high debt levels pose risks. Analyst sentiment is divided with a 50% buy rating, yet the stock's proximity to support levels suggests potential for stability if execution continues. Key risks include subscriber retention and competitive pressures in the fitness market.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →